Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stakeholders Urge Major Changes To Australia's PBS Listing Guidelines

This article was originally published in SRA

Executive Summary

The future shape of Australia's system for listing medicines on the Pharmaceutical Benefits Scheme is becoming clearer after the government published stakeholder responses to a consultation on the long-awaited review of the Pharmaceutical Benefits Advisory Committee guidelines, which are used by the pharmaceutical industry to prepare requests for PBS listing1,2.

Advertisement

Related Content

Australian Industry Concerned Over Comparator Drug, Differing Evidence Levels, As New PBS Guidance Draws Near
Advertisement
UsernamePublicRestriction

Register

PS118442

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel